Eisai
Eisai to Seek Reconsideration of TGA’s Initial Decision on Lecanemab for Alzheimer’s Disease in Australia
Lecanemab, Alzheimer’s disease, Therapeutic Goods Administration (TGA), Eisai, Biogen, reconsideration, Australia
Merck’s Keytruda-Lenvima Combination Shows Promise in Liver Cancer Treatment
Keytruda, Lenvima, liver cancer, hepatocellular carcinoma, combination therapy, Merck, Eisai, clinical trials.
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology
Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders
Accelerating Sales of Eisai and Biogen’s Alzheimer’s Drug Leqembi in Japan
Leqembi, Alzheimer’s drug, Eisai, Biogen, Japan, sales acceleration
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations
Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen
EU Regulatory Panel Rejects Eisai and Biogen’s Leqembi for Alzheimer’s Treatment
Leqembi, Alzheimer’s disease, Eisai, Biogen, European Medicines Agency, regulatory panel, approval rejection, adverse effects
European Regulators Reject Eisai and Biogen’s Alzheimer’s Drug Leqembi
Eisai, Biogen, Leqembi, Alzheimer’s disease, European Medicines Agency, drug rejection
Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization
Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin